The U.S. Food and Drug Administration rejected Eli Lilly’s Biologics License Application, issuing a Complete Response Letter for the company’s PD-1 checkpoint inhibitor sintilimab.
German biotech firm CureVac agreed to an alliance with drugmaker Bayer to get global support in seeking approval for the company’s experimental Covid-19 vaccine and for distribution, the daily Bild reported.
French drugmaker Sanofi SA expects to get approval for the potential COVID-19 vaccine in development with Britain’s GlaxoSmithKline Plc by the first half of 2021, faster than previously anticipated.
Shares of Denmark-based Genmab climbed after the company announced a broad oncology alliance with AbbVie that is valued at close to $4 billion, one of the largest oncology partnerships in the industry.
The Sumitomo Dainippon-Roivant Alliance encompasses up to 11 biopharmaceutical Vants with more than 25 innovative clinical programs and multiple potential product launches from 2020 to 2022, and access to key elements of Roivant’s proprietary technology platforms including DrugOme and Digital Innovation.
Cryoport Inc. and EVERSANA announced a strategic alliance to further create a fully integrated regenerative medicine supply chain solution.
GlaxoSmithKline struck a research deal with the early pioneers of a prominent gene-editing technology at the University of California.
To spur innovation and bolster ties with tech giants, Swiss pharma giant Novartis plans to set up innovation labs across the globe to partner with these companies to spur the development of new therapies.
Evotec announced that Sanofi will be participating in an organized Public Private Partnership to further the discovery of cutting-edge therapeutic drugs in multiple areas.
Pfizer will pay German biotech firm BioNTech up to $425 million in an alliance to develop more effective influenza jabs, the latest major pharma company to bank on a promising new genetic approach.